Fate Therapeutics Inc SEC filings FATE
Fate Therapeutics Inc has 855 filings in SEC EDGAR's recent list, going back to May 2, 2008. Its latest annual report, Form ARS, was filed on Apr 24, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (material agreement, agreement ended). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| ARS | Annual report to shareholders | Apr 24, 2026 | Dec 31, 2025 |
| 10-K | Annual report | Feb 26, 2026 | Dec 31, 2025 |
| ARS | Annual report to shareholders | Apr 17, 2025 | Dec 31, 2024 |
| 10-K | Annual report | Mar 5, 2025 | Dec 31, 2024 |
| ARS | Annual report to shareholders | Apr 26, 2024 | Dec 31, 2023 |
| 10-K | Annual report | Feb 26, 2024 | Dec 31, 2023 |
| ARS | Annual report to shareholders | Apr 21, 2023 | Dec 31, 2022 |
| 10-K | Annual report | Feb 28, 2023 | Dec 31, 2022 |
| 10-K | Annual report | Feb 28, 2022 | Dec 31, 2021 |
| 10-K | Annual report | Feb 24, 2021 | Dec 31, 2020 |
| 10-K | Annual report | Mar 2, 2020 | Dec 31, 2019 |
| 10-K | Annual report | Mar 5, 2019 | Dec 31, 2018 |
| 10-K | Annual report | Mar 5, 2018 | Dec 31, 2017 |
| 10-K | Annual report | Mar 16, 2017 | Dec 31, 2016 |
| 10-K | Annual report | Mar 3, 2016 | Dec 31, 2015 |
| ARS | Annual report to shareholders | Apr 3, 2015 | Dec 31, 2014 |
| 10-K | Annual report | Mar 12, 2015 | Dec 31, 2014 |
| 10-K | Annual report | Mar 17, 2014 | Dec 31, 2013 |
Showing 18 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- FATE (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1434316
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.